National Institute on Drug Abuse holds 114th meeting of National Advisory Council
The spring 2013 meeting of the National Advisory Council on Drug Abuse convened on May 8. APA Fellow and Acting Deputy Director of the National Institute on Drug Abuse (NIDA) David Shurtleff presented the Director’s Report (PDF, 4.64MB) in Director Nora Volkow’s absence and announced he would be leaving NIDA to become deputy director of the National Center on Complementary and Alternative Medicine (NCCAM).
As part of the presentation, Shurtleff provided an update on the Functional Integration of Substance Use, Abuse and Addiction research at NIH. A “common fund” of roughly $10 million will be used to fund specific Funding Opportunity Announcements (FOAs) with NIDA contributing around 70 percent, the National Institute on Alcohol Abuse and Alcoholism (NIAAA) contributing around 22 percent and the National Cancer Institute (NCI) contributing around 8 percent. NIH has already issued FOAs fostering integration to stimulate research on alcohol and other substance use by veterans, effectiveness of alcohol and HIV interventions, and mechanisms of co-addiction to alcohol and nicotine.
Story Landis, PhD, director of the National Institute of Neurological Disorders and Stroke (NINDS) provided an update on the NIH Pain Consortium (PDF, 1.82MB). Betty Tai, PhD, director of NIDA’s Center for Clinical Trials Network (CTN) provided a CTN update (PDF, 8.13MB). Jacques Normand, PhD, director of NIDA’s AIDS Research Program, provided an update on the AIDS Avante-Garde Program (PDF, 1.21MB). Lisa Onken, PhD, chief of the Behavioral and Integrative Treatment Branch, provided a summary of a recent meeting (PDF, 1.10MB) held to examine research on the relationship between nicotine and schizophrenia. Wilson Compton, MD, director of the Division of Epidemiology Services and Prevention Research, described a national strategy and plan (PDF, 3.38MB) to counter prescription drug abuse.
For more information on this issue contact Geoff Mumford.